Use of Biomarkers in Predicting the Onset, Monitoring the Progression, and Risk Stratification for Patients with Type 2 Diabetes Mellitus
- 1 January 2017
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 63 (1) , 186-195
Abstract
BACKGROUND: As the worldwide prevalence of type 2 diabetes mellitus (T2DM) increases, it is even more important to develop cost-effective methods to predict and diagnose the onset of diabetes, monitor progression, and risk stratify patients in terms of subsequent cardiovascular and diabetes complications.CONTENT: Nonlaboratory clinical risk scores based on risk factors and anthropomorphic data can help identify patients at greatest risk of developing diabetes, but glycemic indices (hemoglobin A1c, fasting plasma glucose, and oral glucose tolerance tests) are the cornerstones for diagnosis, and the basis for monitoring therapy. Although family history is a strong predictor of T2DM, only small populations of patients carry clearly identifiable genetic mutations. Better modalities for detection of insulin resistance would improve earlier identification of dysglycemia and guide effective therapy based on therapeutic mechanisms of action, but improved standardization of insulin assays will be required. Although clinical risk models can stratify patients for subsequent cardiovascular risk, the addition of cardiac biomarkers, in particular, high-sensitivity troponin and natriuretic peptide provide, significantly improves model performance and risk stratification.CONCLUSIONS: Much more research, prospectively planned and with clear treatment implications, is needed to define novel biomarkers that better identify the underlying pathogenic etiologies of dysglycemia. When compared with traditional risk features, biomarkers provide greater discrimination of future risk, and the integration of cardiac biomarkers should be considered part of standard risk stratification in patients with T2DM.Keywords
Funding Information
- TIMI Study Group and Brigham and Women's Hospital from AstraZeneca
- Eisai
- Poxel
This publication has 65 references indexed in Scilit:
- Microvesicles/exosomes as potential novel biomarkers of metabolic diseasesDiabetes, Metabolic Syndrome and Obesity, 2012
- Mendelian Randomization Study of B-Type Natriuretic Peptide and Type 2 Diabetes: Evidence of Causal Association from Population StudiesPLOS Medicine, 2011
- Sensitive Cardiac Troponin T Assay and the Risk of Incident Cardiovascular Disease in Women With and Without Diabetes MellitusCirculation, 2011
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesThe Lancet, 2010
- Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic AdultsNew England Journal of Medicine, 2010
- A Sensitive Cardiac Troponin T Assay in Stable Coronary Artery DiseaseNew England Journal of Medicine, 2009
- Natriuretic Peptides/cGMP/cGMP-Dependent Protein Kinase Cascades Promote Muscle Mitochondrial Biogenesis and Prevent ObesityDiabetes, 2009
- Criteria for Evaluation of Novel Markers of Cardiovascular RiskCirculation, 2009
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes MellitusDiabetes, 2009
- Genotype Score in Addition to Common Risk Factors for Prediction of Type 2 DiabetesNew England Journal of Medicine, 2008